{
  "trial_id": "NCT03529955",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Must understand the risks and the benefits/purpose of the study",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Must be 18 years at time of signing the informed consent form",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Willing to participate in all required evaluations and procedures in the study",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patients must have a diagnosis of DM based upon the characteristic cutaneous findings proposed by Sontheimer[6] and/or a skin biopsy consistent with DM.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients must be candidate for systemic therapy for their DM skin disease defined by inadequate response to aggressive sun protection along with the use of potent topical corticosteroids and/or immunomodulators.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patients with a diagnosis of dermatomyositis on steroid-sparing agent and/or systemic steroids (maximum dose of prednisone 1mg/Kg) and still having cutaneous disease activity of at least 5 on the CDASI scale.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "If on immunosuppressive treatments and/or steroids, patients must be on stable doses for at least 4 weeks (28 days).",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients must undergo age appropriate cancer screening.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Females of childbearing potential (FCBP) must have a negative pregnancy test at screening (day 0 of the study and every month throughout the study).",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "While on investigational product and for at least 28 days after taking the last dose of investigational product.",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "Increasing or changing dose of topical therapy within 14 days of study day 0 (including but not limited to topical corticosteroids, tacrolimus, pimecrolimus).",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Increasing or changing systemic steroids dosing within 28 days of study day 0.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "History of any clinically significant (as determined by the investigators) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major uncontrolled disease.",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "The patient is a 16-year-old girl recently diagnosed with myasthenia gravis. She has symptoms of diplopia and weakness affecting her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive.",
  "_meta": {
    "topic_id": "72",
    "trial_id": "NCT03529955",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}